Boston Scientific Corp [BSX] stock prices are up 0.55% to $102.74 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BSX shares have gain 8.09% over the last week, with a monthly amount glided 3.40%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Boston Scientific Corp [NYSE: BSX] stock has seen the most recent analyst activity on April 16, 2025, when Needham upgraded its rating to a Buy but kept the price target unchanged to $113 for it. Previously, Deutsche Bank upgraded its rating to Buy on January 10, 2025, and kept the price target unchanged to $108. On October 18, 2024, downgrade downgraded it’s rating to Hold. Goldman started tracking the stock assigning a Buy rating and suggested a price target of $90 on May 30, 2024. Mizuho upgraded its rating to a Buy and raised its price target to $80 on February 01, 2024. Robert W. Baird started tracking with a Outperform rating for this stock on July 19, 2023, and assigned it a price target of $59. In a note dated June 30, 2023, CL King initiated an Buy rating and provided a target price of $64 on this stock.
The stock price of Boston Scientific Corp [BSX] has been fluctuating between $70.97 and $107.17 over the past year. Currently, Wall Street analysts expect the stock to reach $117.2 within the next 12 months. Boston Scientific Corp [NYSE: BSX] shares were valued at $102.74 at the most recent close of the market. An investor can expect a potential return of 14.07% based on the average BSX price forecast.
Analyzing the BSX fundamentals
The Boston Scientific Corp [NYSE:BSX] reported sales of 17.55B for trailing twelve months, representing a surge of 20.93%. Gross Profit Margin for this corporation currently stands at 0.67% with Operating Profit Margin at 0.18%, Pretax Profit Margin comes in at 0.14%, and Net Profit Margin reading is 0.12%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.1 and Total Capital is 0.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.51.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 101.84 points at the first support level, and at 100.93 for the second support level. However, for the 1st resistance point, the stock is sitting at 103.42, and for the 2nd resistance point, it is at 104.10.
Ratios To Look Out For
It’s worth pointing out that Boston Scientific Corp [NYSE:BSX]’s Current Ratio is 1.08. Also, the Quick Ratio is 0.64, while the Cash Ratio stands at 0.06. Considering the valuation of this stock, the price to sales ratio is 8.66, the price to book ratio is 6.96 and price to earnings (TTM) ratio is 75.36.
Transactions by insiders
Recent insider trading involved Brown Vance R, SVP, GC and Corp. Secretary, that happened on Apr 21 ’25 when 4826.0 shares were sold. Officer, VANCE BROWN completed a deal on Apr 21 ’25 to buy 4826.0 shares. Meanwhile, Chairman, President & CEO Mahoney Michael F sold 0.16 million shares on Apr 01 ’25.
